Oncotarget

Addendum:

Addendum: Resolution of radiation necrosis with bevacizumab following radiation therapy for primary CNS lymphoma

PDF  |  How to cite

Oncotarget. 2022; 13:1165-1165. https://doi.org/10.18632/oncotarget.28292

Metrics: PDF 129 views  |   ?  

Eugene J. Vaios1, Kristen A. Batich2, Anne F. Buckley3, Anastasie Dunn-Pirio4, Mallika P. Patel5, John P. Kirkpatrick1, Ranjit Goudar6 and Katherine B. Peters7,8

1Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA
2Department of Medicine, Division of Medical Oncology, Duke University Medical Center, Durham, NC, USA
3Department of Pathology, Duke University Medical Center, Durham, NC, USA
4Department of Neurology, UC San Diego Health, San Diego, CA, USA
5Department of Pharmacy, Duke University Medical Center, Durham, NC, USA
6Virginia Oncology Associates, Norfolk, VA, USA
7Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA
8Department of Neurology, Duke University Medical Center, Durham, NC, USA

Published: October 20, 2022

Copyright: © 2022 Vaios et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Consent was added to this article: Informed consent was obtained from each patient and the study was approved by our institution.

Original article: Oncotarget. 2022; 13:576–582. DOI: https://doi.org/10.18632/oncotarget.28222


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 28292